{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:25:50Z","timestamp":1707524750200},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,18]]},"DOI":"10.7759\/cureus.29306","type":"journal-article","created":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T05:28:56Z","timestamp":1663565336000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of Short-Term Symptoms Associated With COVID-19 Vaccines Used Among Adolescents in Saudi Arabia"],"prefix":"10.7759","author":[{"given":"Fares K","family":"Alrowdhan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulnasser","family":"Alwably","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulaziz S","family":"Altala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Alfaraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mhd Noor","family":"Farawaty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakan S","family":"Shaheen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suliman A","family":"Alenazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Einas M","family":"Yousef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(21)00012-8","article-title":"COVID-19 vaccine hesitancy in a representative working-age population in France: a survey experiment based on vaccine characteristics","volume":"6","author":"Schwarzinger M","year":"2021","unstructured":"Schwarzinger M, Watson V, Arwidson P, Alla F, Luchini S. COVID-19 vaccine hesitancy in a representative working-age population in France: a survey experiment based on vaccine characteristics. Lancet Public Health. 2021, 6:e210-21. 10.1016\/S2468-2667(21)00012-8","journal-title":"Lancet Public Health"},{"key":"ref2","unstructured":"FDA. Pfizer-BioNTech COVID-19 vaccine emergency use authorization review memorandum. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration. (2020). Accessed: May 1, 2022: https:\/\/www.fda.gov\/media\/144416\/download."},{"key":"ref3","unstructured":"FDA. Pfizer-BioNTech COVID-19 vaccine EUA amendment review memorandum. Silver Spring, MD: US Department of Health and Human Services. (2021). Accessed: May 1, 2022: https:\/\/fda.report\/media\/149528\/nr_EUA+27034.132+Review+Memo+Pfizer-BioNTech+COVID-19+Vaccine_REVISED24May_final.pdf."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7031e1","article-title":"COVID-19 vaccine safety in adolescents aged 12-17 years: United States, December 14, 2020-July 16, 2021","volume":"70","author":"Hause AM","year":"2021","unstructured":"Hause AM, Gee J, Baggs J, et al.. COVID-19 vaccine safety in adolescents aged 12-17 years: United States, December 14, 2020-July 16, 2021. MMWR Morb Mortal Wkly Rep. 2021, 70:1053-8. 10.15585\/mmwr.mm7031e1","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref5","unstructured":"Weaver J. Moderna files for FDA authorization for Covid vaccine in younger teens, adolescents. NBC News. (2021). Accessed: February 1, 2022: https:\/\/www.nbcnews.com\/health\/kids-health\/moderna-files-authorization-covid-vaccine-younger-teens-adolescents-n12702...."},{"key":"ref6","unstructured":"Arab News. Saudi authority approves Moderna vaccine for age group 12-17 years. (2021). Accessed: February 1, 2022: https:\/\/www.arabnews.com\/node\/1915191\/saudi-arabia?utm_medium=email&utm_source=transaction."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15664","article-title":"New-onset neurologic symptoms and related neuro-oncologic lesions discovered after COVID-19 vaccination: two neurosurgical cases and review of post-vaccine inflammatory responses","volume":"13","author":"Einstein EH","year":"2021","unstructured":"Einstein EH, Shahzadi A, Desir L, Katz J, Boockvar J, D'Amico R. New-onset neurologic symptoms and related neuro-oncologic lesions discovered after COVID-19 vaccination: two neurosurgical cases and review of post-vaccine inflammatory responses. Cureus. 2021, 13:e15664. 10.7759\/cureus.15664","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.117607","article-title":"Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review","volume":"428","author":"Sharifian-Dorche M","year":"2021","unstructured":"Sharifian-Dorche M, Bahmanyar M, Sharifian-Dorche A, Mohammadi P, Nomovi M, Mowla A. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review. J Neurol Sci. 2021, 428:117607. 10.1016\/j.jns.2021.117607","journal-title":"J Neurol Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.0600","article-title":"Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine","volume":"325","author":"Shimabukuro T","year":"2021","unstructured":"Shimabukuro T, Nair N. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine. JAMA. 2021, 325:780-1. 10.1001\/jama.2021.0600","journal-title":"JAMA"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piab060","article-title":"Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine","volume":"10","author":"Tano E","year":"2021","unstructured":"Tano E, San Martin S, Girgis S, Martinez-Fernandez Y, Sanchez Vegas C. Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine. J Pediatric Infect Dis Soc. 2021, 10:962-6. 10.1093\/jpids\/piab060","journal-title":"J Pediatric Infect Dis Soc"},{"key":"ref11","unstructured":"Raosoft. Sample size calculator. (2022). Accessed: November 15, 2021: http:\/\/www.raosoft.com\/samplesize.html."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9060674","article-title":"Evaluation of side effects associated with COVID-19 vaccines in Saudi Arabia","volume":"9","author":"Alhazmi A","year":"2021","unstructured":"Alhazmi A, Alamer E, Daws D, et al.. Evaluation of side effects associated with COVID-19 vaccines in Saudi Arabia. Vaccines (Basel). 2021, 9:674. 10.3390\/vaccines9060674","journal-title":"Vaccines (Basel)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase\u00a0I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan MJ","year":"2020","unstructured":"Mulligan MJ, Lyke KE, Kitchin N, et al.. Phase\u00a0I\/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020, 586:589-93. 10.1038\/s41586-020-2639-4","journal-title":"Nature"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2036242","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"384","author":"Skowronski DM","year":"2021","unstructured":"Skowronski DM, De Serres G. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2021, 384:1576-8. 10.1056\/NEJMc2036242","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2021-002933","article-title":"Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: a post-marketing Italian study conducted between 1 January and 28 February 2021 [PREPRINT]","author":"Ossato A","year":"2021","unstructured":"Ossato A, Tessari R, Trabucchi C, Zuppini T, Realdon N, Marchesini F. Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: a post-marketing Italian study conducted between 1 January and 28 February 2021 [PREPRINT]. Eur J Hosp Pharm. 2021, 10.1136\/ejhpharm-2021-002933","journal-title":"Eur J Hosp Pharm"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting","volume":"385","author":"Barda N","year":"2021","unstructured":"Barda N, Dagan N, Ben-Shlomo Y, et al.. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2021, 385:1078-90. 10.1056\/NEJMoa2110475","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-018-0726-5","article-title":"Sex differences in vaccine-induced humoral immunity","volume":"41","author":"Fischinger S","year":"2019","unstructured":"Fischinger S, Boudreau CM, Butler AL, Streeck H, Alter G. Sex differences in vaccine-induced humoral immunity. Semin Immunopathol. 2019, 41:239-49. 10.1007\/s00281-018-0726-5","journal-title":"Semin Immunopathol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.01.071","article-title":"Sex differences in the vaccine-specific and non-targeted effects of vaccines","volume":"29","author":"Flanagan KL","year":"2011","unstructured":"Flanagan KL, Klein SL, Skakkebaek NE, et al.. Sex differences in the vaccine-specific and non-targeted effects of vaccines. Vaccine. 2011, 29:2349-54. 10.1016\/j.vaccine.2011.01.071","journal-title":"Vaccine"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2022.106700","article-title":"COVID-19 vaccines: considering sex differences in efficacy and safety","volume":"115","author":"Jensen A","year":"2022","unstructured":"Jensen A, Stromme M, Moyassari S, Chadha AS, Tartaglia MC, Szoeke C, Ferretti MT. COVID-19 vaccines: considering sex differences in efficacy and safety. Contemp Clin Trials. 2022, 115:106700. 10.1016\/j.cct.2022.106700","journal-title":"Contemp Clin Trials"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/nri2394","article-title":"The X-files in immunity: sex-based differences predispose immune responses","volume":"8","author":"Fish EN","year":"2008","unstructured":"Fish EN. The X-files in immunity: sex-based differences predispose immune responses. Nat Rev Immunol. 2008, 8:737-44. 10.1038\/nri2394","journal-title":"Nat Rev Immunol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1386.043","article-title":"Estrogens and autoimmune diseases","volume":"1089","author":"Cutolo M","year":"2006","unstructured":"Cutolo M, Capellino S, Sulli A, Serioli B, Secchi ME, Villaggio B, Straub RH. Estrogens and autoimmune diseases. Ann N Y Acad Sci. 2006, 1089:538-47. 10.1196\/annals.1386.043","journal-title":"Ann N Y Acad Sci"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.5.2703","article-title":"Hormonal regulation of B cell development: 17 beta-estradiol impairs negative selection of high-affinity DNA-reactive B cells at more than one developmental checkpoint","volume":"176","author":"Grimaldi CM","year":"2006","unstructured":"Grimaldi CM, Jeganathan V, Diamond B. Hormonal regulation of B cell development: 17 beta-estradiol impairs negative selection of high-affinity DNA-reactive B cells at more than one developmental checkpoint. J Immunol. 2006, 176:2703-10. 10.4049\/jimmunol.176.5.2703","journal-title":"J Immunol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/v13030418","article-title":"Target product profile analysis of COVID-19 vaccines in phase III clinical trials and beyond: an early 2021 perspective","volume":"13","author":"Funk CD","year":"2021","unstructured":"Funk CD, Laferri\u00e8re C, Ardakani A. Target product profile analysis of COVID-19 vaccines in phase III clinical trials and beyond: an early 2021 perspective. Viruses. 2021, 13:418. 10.3390\/v13030418","journal-title":"Viruses"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00543-9","article-title":"Risk of serious COVID-19 outcomes among adults with asthma in Scotland: a national incident cohort study","volume":"10","author":"Shi T","year":"2022","unstructured":"Shi T, Pan J, Vasileiou E, Robertson C, Sheikh A. Risk of serious COVID-19 outcomes among adults with asthma in Scotland: a national incident cohort study. Lancet Respir Med. 2022, 10:347-54. 10.1016\/S2213-2600(21)00543-9","journal-title":"Lancet Respir Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01400-4","article-title":"Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis","volume":"23","author":"Castaldo M","year":"2022","unstructured":"Castaldo M, Waliszewska-Pros\u00f3\u0142 M, Koutsokera M, et al.. Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis. J Headache Pain. 2022, 23:41. 10.1186\/s10194-022-01400-4","journal-title":"J Headache Pain"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107456","article-title":"Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents","volume":"385","author":"Frenck RW Jr","year":"2021","unstructured":"Frenck RW Jr, Klein NP, Kitchin N, et al.. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021, 385:239-50. 10.1056\/NEJMoa2107456","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/114641-evaluation-of-short-term-symptoms-associated-with-covid-19-vaccines-used-among-adolescents-in-saudi-arabia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:39:14Z","timestamp":1707507554000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/114641-evaluation-of-short-term-symptoms-associated-with-covid-19-vaccines-used-among-adolescents-in-saudi-arabia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,18]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.29306","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,18]]}}}